2015
Relationship Between Daily Exposure to Biomass Fuel Smoke and Blood Pressure in High-Altitude Peru
Burroughs Peña M, Romero KM, Velazquez EJ, Davila-Roman VG, Gilman RH, Wise RA, Miranda JJ, Checkley W. Relationship Between Daily Exposure to Biomass Fuel Smoke and Blood Pressure in High-Altitude Peru. Hypertension 2015, 65: 1134-1140. PMID: 25753976, PMCID: PMC4466100, DOI: 10.1161/hypertensionaha.114.04840.Peer-Reviewed Original ResearchConceptsDiastolic blood pressureSystolic blood pressureBlood pressureBiomass fuel useHousehold air pollutionVital capacityFuel smokeHigher systolic blood pressurePopulation-based cohort studyDaily exposureHigher diastolic blood pressureBiomass fuel usersBlood pressure outcomesElevated blood pressureHigh blood pressureBiomass fuel smokeMultivariable regression modelsCardiovascular preventionCohort studyLung functionPressure outcomesEffect modificationHigher likelihoodHypertensionFuel users
2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, INVESTIGATORS F. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure 2011, 21: 82-87. PMID: 21830844, DOI: 10.3109/08037051.2011.598699.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBetter SBP controlPrevious antihypertensive medicationsSBP controlAntihypertensive medicationsBaseline predictorsTreatment groupsHigher baseline systolic blood pressureCalcium channel blocker useUncontrolled systolic blood pressureHigher systolic blood pressureBaseline systolic blood pressureMain baseline predictorsUse of thiazidesSystolic BP levelsHigher diastolic BPMultivariable regression modelsLogistic regression modelsACCOMPLISH trialAmlodipine armRandomization armBlocker useCardiovascular outcomesInsulin useSystolic hypertension
2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, Committees and Investigators F. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2006, 152: 500-508. PMID: 16923421, DOI: 10.1016/j.ahj.2006.02.032.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAcute myocardial infarctionMyocardial infarctionReperfusion therapyBaseline characteristicsVALIANT trialLeft ventricular systolic dysfunctionTime of MIAcute Myocardial Infarction trialSafety of captoprilMyocardial Infarction trialPatient baseline characteristicsUse of aspirinVentricular systolic dysfunctionProportion of patientsCare of patientsEvidence-based therapiesMultivariable regression modelsSystolic dysfunctionHeart failureTrial populationKey treatmentPatientsInternational trialInternational guidelines